Market research
IMU.AU Imugene Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 0.23
- Dividend yield
- Not available
- Beta
- 2.24
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000IMU9
- Market cap
- 20M
- P/E ratio
- Not available
- Analyst target
- 0.23
- Dividend yield
- Not available
- Beta
- 2.24
About
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Research context
Imugene Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IMU.AU discussion.
5 years, 6 months ago
Imugene Limited is currently in a long term uptrend where the price is trading 105.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Imugene Limited's total revenue rose by 73.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 26.6% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 38.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Imugene Limited gets an overall score of 4/5.